Literature DB >> 21411599

Successful memory response following a booster dose with a virosome-formulated hepatitis a vaccine delayed up to 11 years.

Christoph Hatz1, Robert van der Ploeg, Bernhard R Beck, Gert Frösner, Marjory Hunt, Christian Herzog.   

Abstract

Boosting adult travelers with the virosome-formulated, aluminum-free hepatitis A vaccine Epaxal up to 128 months after a single primary dose confers full protection against hepatitis A, even in travelers aged 50 years and above. Delaying the booster dose did not influence the immune memory response to Epaxal.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21411599      PMCID： PMC3122528          DOI： 10.1128/CVI.00358-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  13 in total

1.  Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine.

Authors:  J B Cederna; D Klinzman; J T Stapleton
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

2.  Hepatitis A vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2000-02-04

3.  Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose.

Authors:  P Landry; S Tremblay; R Darioli; B Genton
Journal:  Vaccine       Date:  2000-10-15       Impact factor: 3.641

4.  Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.

Authors:  Bernhard R Beck; Christoph Hatz; Rainer Brönnimann; Christian Herzog
Journal:  Clin Infect Dis       Date:  2003-09-30       Impact factor: 9.079

5.  Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine.

Authors:  Sten Iwarson; Magnus Lindh; Lena Widerström
Journal:  J Travel Med       Date:  2004 Mar-Apr       Impact factor: 8.490

6.  Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.

Authors:  Patrick A Bovier; Jürgen Bock; Tiziana Farinelli Ebengo; Gert Frösner; Jacqueline Glaus; Christian Herzog; Louis Loutan
Journal:  J Med Virol       Date:  2010-10       Impact factor: 2.327

7.  Serology and interferon production during the early phase of acute hepatitis A.

Authors:  R Zachoval; M Kroener; M Brommer; F Deinhardt
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

8.  Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.

Authors:  Valérie D'Acremont; Christian Herzog; Blaise Genton
Journal:  J Travel Med       Date:  2006 Mar-Apr       Impact factor: 8.490

9.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Annemarie Wasley; Beth P Bell
Journal:  MMWR Recomm Rep       Date:  2006-05-19

10.  The effect of age and weight on the response to formalin inactivated, alum-adjuvanted hepatitis A vaccine in healthy adults.

Authors:  P D Reuman; P Kubilis; W Hurni; L Brown; D Nalin
Journal:  Vaccine       Date:  1997-07       Impact factor: 3.641
View more
  6 in total

1.  Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose.

Authors:  Xiaoshu Zhang; Jing An; Aixia Tu; Xuefeng Liang; Fuqiang Cui; Hui Zheng; Yu Tang; Jianfeng Liu; Xuxia Wang; Ningjing Zhang; Hui Li
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

Review 2.  Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines - A systematic review.

Authors:  Anke L Stuurman; Cinzia Marano; Eveline M Bunge; Laurence De Moerlooze; Daniel Shouval
Journal:  Hum Vaccin Immunother       Date:  2016-10-27       Impact factor: 3.452

Review 3.  Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Authors:  Christian Herzog; Koen Van Herck; Pierre Van Damme
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

Review 4.  Virosome-based nanovaccines; a promising bioinspiration and biomimetic approach for preventing viral diseases: A review.

Authors:  Khatereh Asadi; Ahmad Gholami
Journal:  Int J Biol Macromol       Date:  2021-04-16       Impact factor: 6.953

5.  Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.

Authors:  Yeong-Jun Song; Jiseun Lim; Woong-Sub Park; Haesook Sohn; Moo-Sik Lee; Dong-Hoon Shin; Chun-Bae Kim; Hwasung Kim; Gyung-Jae Oh; Moran Ki
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

6.  The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient?

Authors:  Desmond Curran; Marc de Ridder; Thierry Van Effelterre
Journal:  Hum Vaccin Immunother       Date:  2016-07-18       Impact factor: 3.452
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.